JPRN-UMIN000020735招募中未知
Randomized controlled trial to apply personalized medicine to treatment-resistant depression with mixed feature. - Personalized medicine for treatment-REsistant depression with MIXed feature(REMIX)
Kansai Medical University, Osaka, Japan0 个研究点目标入组 150 人开始时间: 2016年2月14日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 150
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Patients who meet DSM5 for significant Axis I and II disorders except major depressive disorder. Patients who have a ECT therapy within 3 months prior to study entree. Patients who are comatose and strongly affected by central nervous system. Patients known to have a history or complication of allergy to aripiprazole. Patients with a history or a complication of diabetes. Women who are pregnant, possibly pregnant, or breast-feeding. Patients who have been judged by the investigator to be inappropriate for inclusion in the trial for any other reasons Patients who have been judged by the investigators to have a high risk of suicide.
研究者
相似试验
尚未招募
不适用
Personalised Post-operative monitoring and fluid therapy vs standard of care in recipients of Living donor kidney transplantACTRN12622001093774Kidney, Transplant and Diabetes Research Australia24
进行中（未招募）
不适用
Effectiveness of a personalised smoking cessation smartphone app among Malaysian adult smokersSmoking cessationISRCTN91299538niversity of Malaya286
招募中
Unknown
Evaluation of ALDH2 genotyping for health promotiondesirable lifestyle habitsJPRN-UMIN000050580Saga University650
已完成
2 期
Randomized Phase II clinical trial of personalized peptide vaccination for HCV positive patients with advanced liver cancer.liver cancerJPRN-UMIN000003520Kurume University Research Center for Innovative Cancer Therapy, Clinical Research Division84
已完成
2 期
Randomized Phase II clinical trial of personalized peptide vaccination for patients with advanced (stage IIIB/IV) or recurrence non-small cell lung cancer who had chemotheraphy of 1 or 2 regimen, to evaluate the progression free survial of docetaxel plus placebo versus docetaxel plus pesonalized pepitide vaccine.non-small cell lung cancerJPRN-UMIN000003521Kurume University Research Center for Innovative Cancer Therapy, Clinical Research Division64